{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:23:12Z","timestamp":1762327392537,"version":"build-2065373602"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018623","name":"Quanzhou City Science and Technology Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Antibiot."],"abstract":"<jats:p>Co-administration of simnotrelvir\/ritonavir with voriconazole should be avoided, as stated in the product insert of simnotrelvir\/ritonavir, due to the anticipated decrease in the plasma concentration of voriconazole. Currently, there are no published reports regarding a pharmacokinetic interaction between simnotrelvir\/ritonavir and voriconazole. We present the case of an 88-year-old man with pulmonary aspergillosis and coronavirus disease 2019 (COVID-19) co-infection treated concurrently with voriconazole and simnotrelvir\/ritonavir. Prior to initiating simnotrelvir\/ritonavir, two trough concentrations of voriconazole were measured, yielding values of 2.8 and 2.6 mg\/L. After 2 days of co-administration with simnotrelvir\/ritonavir, the voriconazole trough concentration rose to 6.0 mg\/L. The voriconazole dose was subsequently reduced by 25%, and simnotrelvir\/ritonavir was discontinued after completion of the standard 5-day course. A week after voriconazole dose reduction (4 days after simnotrelvir\/ritonavir withdrawal), the trough concentration was measured again and was found to be 3.5 mg\/L. This case indicates that the trough concentration of voriconazole increased significantly during co-administration with simnotrelvir\/ritonavir. Moreover, the interaction persisted even after discontinuation of simnotrelvir\/ritonavir, necessitating dynamic dose adjustments guided by therapeutic drug monitoring.<\/jats:p>","DOI":"10.3389\/frabi.2025.1705987","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:25:52Z","timestamp":1762323952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of drug\u2013drug interaction between voriconazole and simnotrelvir\/ritonavir"],"prefix":"10.3389","volume":"4","author":[{"given":"Tingting","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic-pharmacokinetic prospective multicenter study","volume":"40","author":"Blanco-Dorado","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized medication of voriconazole: A practice guideline of the division of therapeutic drug monitoring, chinese pharmacological society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"B5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-2600(23)00408-3","article-title":"Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis","volume":"12","author":"Gioia","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B9","doi-asserted-by":"publisher","first-page":"11851193","DOI":"10.1007\/s002280162089y","article-title":"Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis","volume":"72","author":"Li","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1616061","article-title":"Unexpected voriconazole toxicity due to nirmatrelvir\/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring","volume":"16","author":"L\u00f3pez-Hern\u00e1ndez","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1654671","article-title":"Plasma concentration of voriconazole under concomitant use of nirmatrelvir\/ritonavir in patients with COVID-19: a multicenter retrospective study","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-asian and asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.3222","article-title":"Physiologically based pharmacokinetic modeling to investigate the disease-drug-drug interactions between voriconazole and nirmatrelvir\/ritonavir in COVID-19 patients with CYP2C19 phenotypes","volume":"116","author":"Wang","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmi.2024.09.007","article-title":"Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial","volume":"31","author":"Ye","year":"2025","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Frontiers in Antibiotics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frabi.2025.1705987\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:25:52Z","timestamp":1762323952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frabi.2025.1705987\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":17,"alternative-id":["10.3389\/frabi.2025.1705987"],"URL":"https:\/\/doi.org\/10.3389\/frabi.2025.1705987","relation":{},"ISSN":["2813-2467"],"issn-type":[{"value":"2813-2467","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1705987"}}